Ablynx to discover antibody-based ion channel modulators for Merck & Co
This article was originally published in Scrip
Executive Summary
Belgian firm Ablynx has signed a deal with Merck & Co in the neuroscience space to develop Nanobody candidates directed towards a voltage gated ion channel with the option to develop a Nanobody to a second target.